These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 23714382)

  • 1. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
    Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Progression of Persistent Nondysplastic Barrett's Esophagus to Malignancy.
    Peters Y; Honing J; Kievit W; Kestens C; Pestman W; Nagtegaal ID; van der Post RS; Siersema PD
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):869-877.e5. PubMed ID: 30213587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
    Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
    Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
    Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus.
    Nguyen T; Thrift AP; Yu X; Duan Z; El-Serag HB
    Am J Gastroenterol; 2017 Jul; 112(7):1049-1055. PubMed ID: 28244499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
    Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
    United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
    Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
    Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma.
    Solanky D; Krishnamoorthi R; Crews N; Johnson M; Wang K; Wolfsen H; Fleischer D; Ramirez FC; Katzka D; Buttar N; Iyer PG
    J Clin Gastroenterol; 2019; 53(5):361-365. PubMed ID: 29608452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of body mass index on the prevalence and progression of dysplasia in Barrett's esophagus: a retrospective analysis (.).
    Thota PN; Arora Z; Benjamin T; Pagadala M; Lopez R; Sanaka MR
    Scand J Gastroenterol; 2016 Nov; 51(11):1288-93. PubMed ID: 27460942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.
    Wani S; Falk G; Hall M; Gaddam S; Wang A; Gupta N; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Reddymasu S; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Lieberman DA; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2011 Mar; 9(3):220-7; quiz e26. PubMed ID: 21115133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
    Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
    Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
    Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
    Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrett's Registry Collaboration of academic centers in Ireland reveals high progression rate of low-grade dysplasia and low risk from nondysplastic Barrett's esophagus: report of the RIBBON network.
    O'Byrne LM; Witherspoon J; Verhage RJJ; O'Brien M; Muldoon C; Ryan C; Buckley M; Murphy T; Reynolds R; Patchett S; Kay E; Azam H; Robb W; Arumugasamy M; Mathuna PM; Leyden J; Gargan S; Doherty G; Sheahan K; Collins C; Nath A; O'Sullivan J; Donohoe CL; Ravi N; O'Toole D; Reynolds JV
    Dis Esophagus; 2020 Oct; 33(10):. PubMed ID: 32193532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patients.
    Tokunaga M; Okimoto K; Akizue N; Ishikawa K; Hirotsu Y; Amemiya K; Ota M; Matsusaka K; Nishimura M; Matsushita K; Ishikawa T; Nagashima A; Shiratori W; Kaneko T; Oura H; Kanayama K; Ohta Y; Taida T; Saito K; Matsumura T; Chiba T; Mochizuki H; Arai M; Kato J; Ikeda JI; Omata M; Kato N
    Sci Rep; 2021 Sep; 11(1):17671. PubMed ID: 34480065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population.
    Nguyen TH; Thrift AP; George R; Rosen DG; El-Serag HB; Ketwaroo GA
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):e876-e889. PubMed ID: 33839273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance in Barrett's esophagus: an audit of practice.
    Ajumobi A; Bahjri K; Jackson C; Griffin R
    Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.